Search
GlaxoSmithKline to Acquire Efimosfermin, a Promising Fatty Liver Disease Treatment, for $2 Billion
2025-05-14 /
Read about 0 minute
Author：小编
The British pharmaceutical giant GlaxoSmithKline (GSK) has announced its intent to acquire efimosfermin, a promising drug for treating liver disease, from Boston Pharmaceuticals for a total consideration of up to $2 billion. This acquisition will be finalized through the purchase of BP Asset IX, a subsidiary of Boston Pharmaceuticals. The deal structure includes an initial payment of $1.2 billion, with potential additional milestone payments totaling up to $800 million. Efimosfermin, currently in Phase III clinical trials, aims to treat and prevent fatty liver disease, showcasing significant potential in reversing liver fibrosis.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
